NEWTOWN SQUARE, Pa.―Kibow Biotech, Inc. (a suburban Philadelphia-based company) announced today at Renal Week that it is changing the brand name of its flagship product to "RENADYL™." Formerly known as Kibow® Biotics, this patented and clinically tested probiotic formulation helps maintain healthy kidney function, Kibow reported. Kibow has opted for the name change because, under the former appellation, "Kibow® Biotics," the 100-percent natural product was perceived as an antibiotic drug by many consumers. The newly trade named "RENADYL™" will continue to be sold exclusively via the company's own online store.
Recent recipient of a U.S.-stimulus-package grant and having benefited from a renewed licensing agreement for another probiotic formulation targeting animal health, Kibow Biotech, Inc. is at a pivotal point in its mission to educate healthcare professionals, service providers, and consumers about the advantages of probiotics, according to Kibow. The company has been developing and promoting probiotic products in support of renal health for more than 12 years.
RENADYL™ is targeted toward kidney health and helps improve the quality of life in chronic kidney failure (CKF) persons who also adhere to their routine standardized care of treatment for their pre-existing medical conditions.
Kibow's human clinical trials, involving dialysis and pre-dialysis patients, are currently under way at Thomas Jefferson University, Philadelphia, and at Downstate Medical Center/Kings County Hospitals, State University of New York (SUNY), Brooklyn, N.Y. Another trial, to be conducted at Mayo clinic, Rochester, Minn., is soon to begin.
